Werewolf Therapeutics, INC Schedule 13D activist filings

RA Capital Management and affiliated entities have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of Werewolf Therapeutics, Inc. common stock.

RA Capital Management has disclosed a series of open market sales reducing its beneficial ownership in Werewolf Therapeutics, Inc. to 6.0%.

RA Capital Management has disclosed a reduction in its beneficial ownership of Werewolf Therapeutics common stock through a series of open market sales.

RA Capital Management reports a reduction in its beneficial ownership of Werewolf Therapeutics common stock following recent open market sales.

A group of investment entities affiliated with MPM Capital reported the sale of Werewolf Therapeutics common stock in the open market between May 6 and May 12, 2026.

MPM BioVentures and affiliated entities have disclosed the sale of shares in Werewolf Therapeutics, Inc. via an amended Schedule 13D filing.

Several key reporting persons, including MPM BioVentures and UBS Oncology Impact Fund, have reduced their beneficial ownership in Werewolf Therapeutics through open market sales.

Key investment funds and their managing directors have significantly reduced their beneficial ownership in Werewolf Therapeutics through open market sales.

Key institutional investors and insiders, including MPM BioVentures and UBS Oncology Impact Fund, have reported significant open market sales of Werewolf Therapeutics common stock.

An investor group led by MPM BioImpact and its affiliates reported open market sales of Werewolf Therapeutics common stock, reducing their collective beneficial ownership.

RA Capital Management, L.P. and its affiliates updated their beneficial ownership in Werewolf Therapeutics, Inc. to 13.8% of common stock, reflecting an increase in the issuer's outstanding shares and a director's departure.

MPM BioVentures and affiliated entities reported open market sales of Werewolf Therapeutics common stock, reducing their collective beneficial ownership.

RA Capital Management, L.P. and its affiliates have increased their beneficial ownership in Werewolf Therapeutics, Inc. to 15.0% through recent open market purchases.